Company advancing plans to expand the FUROSCIX franchise to include an 80mg/1ml auto-injector as an additional delivery system designed to provide greater flexibility to heart failure patients
Agency confirms no additional clinical data required to pursue label expansion of FUROSCIX into chronic kidney disease (CKD)
https://finance.yahoo.com/news/scpharmaceuticals-announces-positive-feedback-two-120000866.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.